RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures

Phase 2 Recruiting 216 enrolled Supernus Pharmaceuticals, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase 2 double-blind, randomized, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy, safety, and tolerability of SPN-817 in adults with focal onset seizures.

Timeline

Start: 2024-12-30
Primary completion: 2027-08
Completion: 2027-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SPN-817	Unknown	3 mg	—
Subject	SPN-817	Unknown	4 mg	—

RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures

Summary

Timeline

Drugs

Indications